Key Stats
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
Stock Score/grades
The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company
- Altman Z Score 0.55
- Piotroski Score 6.00
- Grade Outperform
- Symbol (TAK)
- Company Takeda Pharmaceutical Company Limited
- Price $13.86
- Changes Percentage (0.51%)
- Change $0.07
- Day Low $13.82
- Day High $13.90
- Year High $15.08
Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan, the United States, Europe, Canada, Latin America, Russia, rest of Asia, and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma derived therapies, oncology, and neuroscience. The company provides its products under the Entyvio, Gattex/Revestive, Takecab, Alofisel, Dexilant, Natpara, Adynovate/Adynovi, Takhzyro, Livtencity, Elaprase, Replagal, Advate, Vpriv, Gammagard Liquid/Kiovig, Hyqvia, Cuvitru, Exkivity, Velcade, Leuplin/Enantone, Adcetris, Vyvansese, Trintellix, and Alunbrig brands. Takeda Pharmaceutical Company Limited has out-licensing agreement with Neurocrine Biosciences, Inc.; collaborations and in-licensing agreements with the University of Texas MD Anderson Cancer Center, Arrowhead Pharmaceuticals Inc., and Ovid Therapeutics Inc.; and collaboration with Evox Therapeutics Ltd., as well as a licensing agreement with ProThera Biologics Inc. It also has research collaboration and licensing agreement with Crescendo Biologics, Code Bio, Immusoft, Poseida Therapeutics, Selecta Biosciences, BridGene Biosciences, Skyhawk Therapeutics, and StrideBio; and strategic alliances with Egle Therapeutics SAS; Evotec SE; Neurocrine Biosciences, Inc.; Carmine Therapeutics; KSQ Therapeutics; and Anima Biotech. Takeda Pharmaceutical Company Limited was founded in 1781 and is headquartered in Tokyo, Japan.
- Last Earnings N/A
- Ex-Dividend for 5/16 Dividend 09/30/2024
- Dividend Payable N/A
- Today N/A
- Next Earnings (Estimated) 01/29/2025
- Fiscal Year End N/A
- Average Stock Price Target $0.00
- High Stock Price Target $0.00
- Low Stock Price Target $0.00
- Potential Upside/Downside N/A
- Consensus Rating Buy
- Rating Score (0-4) N/A
- Research Coverage N/A
- EPS (Most Recent Fiscal Year) $0.29
- Trailing P/E Ratio 46.45
- Forward P/E Ratio 46.45
- P/E Growth 46.45
- Net Income $144.07 B
Income Statement
Quarterly
Annual
Latest News of TAK
The Latest News section aggregates recent news posts from various news outlets, offering a comprehensive overview of the most recent developments related to the topic.
-
Let's Discuss: 'Two Young Drivers Take the Wheel. One, a Teen. The Other, a Tesla.'
Join "Conversations With Journalists" to discuss a New York Times article with a Times journalist and teens worldwide. Explore driving, self-driving cars, and how automated vehicles may impact the fut...
By The New York Times | 17 hours ago -
Billionaire Jeff Yass Sold 61% of Susquehanna's Stake in Palantir and Is Piling Into Another Headline-Grabbing Artificial Intelligence (AI) Stock
The rise of AI is a major trend on Wall Street, with PwC predicting a $15.7 trillion boost to global GDP by 2030. Billionaire investors like Jeff Yass of Susquehanna are closely watched for their move...
By Yahoo! Finance | 17 hours ago -
Democrats suffer a drubbing: 10 key takeaways from Trump's election win
Kamala Harris failed to win the presidency as Donald Trump's bombastic style and extreme proposals resonated with over 70 million voters. She lost in key swing states, missing the opportunity to becom...
By The Guardian | 17 hours ago
